Boston Scientific ( BSX) said it has completed its stent recall, but shares stumbled another 5% Tuesday as Wall Street and investors continued to fear the worst is not yet over for the company. In a Webcast with doctors Tuesday, the company said that it had completed its recall of Taxus stents, a heart device used to keep arteries open and unclogged after a balloon angioplasty procedure, and had begun restocking hospitals with new units. Last Friday, Boston Scientific announced that it was widening its recall of two different stents, which have been linked to three deaths and more than 40 serious injuries. But while the company has pulled faulty versions of Taxus from the shelves, it has done so at the expense of its own reputation with doctors and Wall Street. When the first sign of trouble emerged on July 2, Boston Scientific only recalled 200 stents and said manufacturing defect affected two production lots. After closer inspection, the company found the issue was more widespread. As a result, Prudential Equity Group downgraded the company to neutral from overweight on Tuesday, dropping its price target to $40 from $53, lowering earnings estimates going forward and telling investors the recall gaffe will likely cost it market share in the lucrative stent market. "This recall is clearly not going as we expected. Initial checks on Friday indicated that doctors would take the recall as fairly routine," said Robert Faulkner, analyst at Prudential, in his downgrade. "As the day wore on yesterday, it became clear that opinion leaders, especially, grew profoundly irritated as the considered the evolution of the recall." (Prudential does not have an investment banking business and Faulkner does not own shares of the company.) Shares of the company, which have dropped 19.1% since the initial recall was announced on July 2, were off another $1.77 to $34.38 Tuesday.